Key terms

About FOLD

Amicus Therapeutics, Inc. operates as a biotechnology company. The firm focuses on discovering, developing and delivering medicines for people living with metabolic diseases. Its product portfolio includes first and only approved oral precision medicine for people living with Fabry disease who have amenable genetic variants, a novel, clinical-stage, treatment paradigm for Pompe disease and a rare disease gene therapy portfolio. The company was founded by John Francis Crowley on February 4, 2002 and is headquartered in Princeton, NJ.

Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
     
52-week range
     
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date

Key terms

Smart score

Latest FOLD news

Mar 18 7:13am ET Amicus price target lowered to $19 from $21 at JPMorgan by TipRanks Mar 06 6:19am ET Amicus’s Growth Trajectory Reinforces Buy Rating Amid Strong Product Prospects and Revenue Milestones by TipRanks Mar 01 5:21am ET Analysts’ Opinions Are Mixed on These Healthcare Stocks: Amicus (FOLD), Xenon (XENE) and Veeva Systems (VEEV) by TipRanks Mar 01 1:04am ET Buy Rating Affirmed: Amicus’s Strong Product Launch and Growth Trajectory by TipRanks Feb 29 5:40am ET Analysts Offer Insights on Healthcare Companies: Alignment Healthcare (ALHC), TG Therapeutics (TGTX) and Amicus (FOLD) by TipRanks Feb 29 5:29am ET Needham Sticks to Its Hold Rating for Amicus (FOLD) by TipRanks Feb 28 3:15pm ET Buy Rating Affirmed for Amicus with Strong Growth and Promising Outlook by TipRanks Feb 28 7:07am ET Amicus reports Q4 EPS 1c, consensus (6c) by TipRanks Jan 09 8:28am ET Needham Sticks to Their Hold Rating for Amicus (FOLD) by TipRanks Jan 09 6:40am ET Analysts Offer Insights on Healthcare Companies: Sarepta Therapeutics (SRPT), Danaher (DHR) and Amicus (FOLD) by TipRanks Jan 09 6:40am ET Amicus (FOLD) Receives a Buy from TD Cowen by TipRanks Jan 09 12:59am ET Leerink Partners Sticks to Its Buy Rating for Amicus (FOLD) by TipRanks Jan 08 5:33am ET Amicus’ (NASDAQ:FOLD) 2023 Sales Exceed Expectations by TipRanks Jan 07 5:03pm ET Amicus reports preliminary FY23 revenue $399.4M, consensus $396.45M by TipRanks Dec 25 12:40am ET Analysts’ Top Healthcare Picks: Hookipa Pharma (HOOK), Immunovant (IMVT) by TipRanks Dec 24 6:17am ET ‘Time to Pull the Trigger,’ Says Morgan Stanley About These 2 Healthcare Stocks by TipRanks

No recent press releases are available for FOLD

FOLD Financials

1-year income & revenue

Key terms

FOLD Forecasts

analyst rating

  • buy
  • hold
  • sell

We're sorry, but this
information is
temporarily unavailable.

1-year stock price forecast

FOLD Competitors

$ Market cap P/E ratio $ Price 1d change 52-week range

Key terms

Latest investing news

NEW YORK, NEW YORK - FEBRUARY 08: A New York Community Bank stands in Brooklyn on February 08, 2024 in New York City. New York Community Bancorp, a regional lender, shed about 60% of its value over the past eight days and its credit rating has been downgraded to Junk by Moody's. (Photo by Spencer Platt/Getty Images)
Spencer Platt/Getty Images
US regional banks are still under pressure. That’s likely to continue
Trump Media, which runs the social media platform Truth Social, took the place of Digital World's place on the Nasdaq stock exchange in March.
Frank Franklin II/AP
Trump Media stock ends session 15% higher after two very bad days
Students at Highlands High School, work on a practice test at the ACT Boot Camp in Newport, Ky.
Patrick Reddy/The Enquirer/AP/File
Private equity finds its next bet: college admissions
In this photo illustration, Republican presidential candidate former President Donald Trump's social media platform Truth Social is shown on a cell phone on March 25, 2024 in Chicago, Illinois.
Scott Olson/Getty Images
Trump’s stock tumbles again after Truth Social announces it’s getting into streaming